ING Group’s Galectin Therapeutics GALT Stock Holding History

ING Group’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,000	Closed	-$318K	–	803
2018 Q2	$318K	Buy	+50,000	New	+$244K	0.01%	610

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FFA

First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

ING Group's GALT Position: Q3 2018 in Review

ING Group sold out of Galectin Therapeutics (GALT) in Q3 2018, closing a stake of 50,000 shares — an estimated $318K sold.

ING Group first reported a position in GALT in Q2 2018 and held it in 1 quarter. The position peaked at $318K in Q2 2018. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2018.

ING Group reported no remaining Galectin Therapeutics position as of Q3 2018 after selling out during the quarter.
ING Group sold 50,000 Galectin Therapeutics shares in Q3 2018, an estimated $318K.
ING Group first reported a position in Galectin Therapeutics in Q2 2018 and held it in 1 quarter.
ING Group's Galectin Therapeutics position peaked at $318K in Q2 2018.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2018.

Based on ING Group's 13F filing for Q3 2018, filed 6 Nov 2018.